The Challenge of Assessing Cell Therapy Engraftment

Verifying the in vivo viability and function of induced pluripotent stem cell (iPSC)-derived neuronal grafts is a primary objective in preclinical development for neurodegenerative disorders. For Parkinson’s disease programs, sponsors must demonstrate that transplanted dopaminergic neurons survive, integrate into host circuitry, and restore dopaminergic tone.

Traditional reliance on behavioral scoring and post-mortem histology provides valuable but incomplete data. These methods offer only a terminal snapshot and can be confounded by compensatory mechanisms or placebo effects, making it difficult to directly attribute functional recovery to the therapeutic graft.

Integrating Multimodal Imaging for Definitive Data

A longitudinal, multimodal imaging strategy provides direct, quantitative evidence of graft performance over the entire study duration. By combining PET and MRI, we can visualize both the structural and functional characteristics of the cell therapy product in vivo.

• Structural MRI: Delivers high-resolution anatomical detail to confirm graft placement, measure volume over time, and monitor the surrounding tissue for any signs of inflammation or adverse reactions.

• Functional PET: Utilizes specific radiotracers to measure biological processes. For dopaminergic grafts, this includes quantifying dopamine transporter (DAT) density, a direct marker of viable, functional neurons.

This dual-modality approach generates a robust, translatable dataset that directly links the physical presence of the graft to its intended biological function, strengthening the rationale for clinical progression.

Translational Insights from Advanced Therapeutic Platforms

The value of establishing clear, objective endpoints is a consistent theme across advanced therapy development. For instance, studies evaluating AAV-based gene therapies have shown that demonstrating a favorable safety profile alongside therapeutic benefit across relevant species is a key driver of program success (PMID: 35333110). Longitudinal imaging provides this exact type of robust safety and efficacy data for cell therapies.

Similarly, the development of platform technologies, such as LNP-based mRNA delivery, underscores the need for analytical methods that can validate the core mechanism independent of the specific genetic target (PMID: 39001827). For iPSC-derived therapies, imaging serves this purpose by directly assessing the performance of the cell product itself: its ability to survive, engraft, and mature.